Literature DB >> 12858342

Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter.

Sohei Kitazawa1, Kazuyoshi Kajimoto, Takeshi Kondo, Riko Kitazawa.   

Abstract

Receptor activator of NF-kappaB ligand (RANKL) has been identified as requisite for osteoclastogenesis. To elucidate the molecular mechanism that conducts its catabolic action on bone, the effect of 1alpha,25 dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) on osteoclastogenesis and RANKL mRNA expression was examined by coculture, RT-PCR and nuclear run-on studies. By accelerating the transcription rate of the RANKL gene in SaOS2 osteoblastic cells, 1alpha,25(OH)(2)D(3) enhanced in vitro osteoclast formation from peripheral monocytes. Cloning and characterization of the 5'-flanking region of the human RANKL gene revealed that the basic promoter comprises inverted TATA- and CAAT-boxes flanked by RUNX2 binding sites. Both electrophoresis mobility shift assay (EMSA) and transfection studies demonstrated that 1alpha,25(OH)(2)D(3) activated human RANKL promoter through vitamin D responsive elements (VDRE) located at -1584/-1570 by binding VDR and RXRalpha heterodimers in a ligand-dependent manner. The results provide direct evidence that 1alpha,25(OH)(2)D(3) augments osteoclastogenesis by transactivating the human RANKL gene in osteoblastic cells through VDRE. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858342     DOI: 10.1002/jcb.10567

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  39 in total

Review 1.  DNA damage, apoptosis and langerhans cells--Activators of UV-induced immune tolerance.

Authors:  Laura Timares; Santosh K Katiyar; Craig A Elmets
Journal:  Photochem Photobiol       Date:  2008-01-29       Impact factor: 3.421

Review 2.  The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature.

Authors:  Keith A Hruska; Suresh Mathew; Richard J Lund; Imran Memon; Georges Saab
Journal:  Semin Nephrol       Date:  2009-03       Impact factor: 5.299

Review 3.  Biology and Mechanisms of Action of the Vitamin D Hormone.

Authors:  J Wesley Pike; Sylvia Christakos
Journal:  Endocrinol Metab Clin North Am       Date:  2017-09-29       Impact factor: 4.741

4.  Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer.

Authors:  Qiang Fu; Stavros C Manolagas; Charles A O'Brien
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.

Authors:  D Fernández-García; M Muñoz-Torres; P Mezquita-Raya; M de la Higuera; G Alonso; R Reyes-García; A Sebastian Ochoa; M E Ruiz-Requena; J Dios Luna; F Escobar-Jiménez
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

6.  The role of periodontal ligament cells in delayed tooth eruption in patients with cleidocranial dysostosis.

Authors:  Stefan Lossdörfer; Bassel Abou Jamra; Birgit Rath-Deschner; Werner Götz; Rami Abou Jamra; Bert Braumann; Andreas Jäger
Journal:  J Orofac Orthop       Date:  2009-12-04       Impact factor: 1.938

7.  Transcriptional regulation of human RANK ligand gene expression by E2F1.

Authors:  Yan Hu; Meng Sun; Nagalakshmi Nadiminty; Wei Lou; Elaine Pinder; Allen C Gao
Journal:  Biochem Biophys Res Commun       Date:  2008-03-31       Impact factor: 3.575

8.  A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression.

Authors:  Kathleen A Bishop; Mark B Meyer; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2009-10-30

Review 9.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

10.  Snail1 controls bone mass by regulating Runx2 and VDR expression during osteoblast differentiation.

Authors:  Cristina A de Frutos; Romain Dacquin; Sonia Vega; Pierre Jurdic; Irma Machuca-Gayet; M Angela Nieto
Journal:  EMBO J       Date:  2009-02-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.